Your browser doesn't support javascript.
loading
Use of High-Dose Androgens Is Associated with Reduced Brain-Derived Neurotrophic Factor in Male Weightlifters.
Bjørnebekk, Astrid; Scarth, Morgan; Neupane, Sudan Prasad; Westlye, Lars T; Hullstein, Ingunn R; Thorsby, Per Medbøe; Halvorsen, Bente.
Afiliação
  • Bjørnebekk A; Section for Clinical Addiction Research, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
  • Scarth M; Section for Clinical Addiction Research, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
  • Neupane SP; National Centre for Suicide Research and Prevention, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Westlye LT; Department of Psychology, University of Oslo, Oslo, Norway.
  • Hullstein IR; Division of Mental Health and Addiction, Norwegian Centre for Mental Disorders Research (NORMENT), Oslo University Hospital, Oslo, Norway.
  • Thorsby PM; Norwegian Doping Control Laboratory, Oslo University Hospital, Oslo, Norway.
  • Halvorsen B; Department of Medical Biochemistry and Biochemical Endocrinology and Metabolism Research Group, Hormone Laboratory, Oslo University Hospital, Aker, Oslo, Norway.
Neuroendocrinology ; 113(1): 36-47, 2023.
Article em En | MEDLINE | ID: mdl-35944495
ABSTRACT

INTRODUCTION:

Use of high-dose androgens causes drastic changes in hormonal milieu and is associated with adverse medical, psychological, and cognitive effects. Brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family of growth factors plays a critical role in neuroplasticity, with implications for cognitive function and mental health. The impact of long-term, high-dose androgen use on BDNF in a natural setting has not been investigated. This study examined the association between long-term androgen exposure and BDNF levels, and the links between BDNF, heavy resistance exercise, hormones, androgens, and mental health.

METHODS:

We measured serum levels of BDNF and sex steroid hormones in male weightlifters (N = 141) with a history of current (n = 59), past (n = 29), or no (n = 52) androgen use. All participants completed questionnaires assessing maximum strength and measures of anxiety and depression. Group differences in BDNF were tested using general linear models adjusting for age and associations between BDNF and strength, anxiety, and depression using Pearson's or Kendall's correlations.

RESULTS:

Both current (mean 44.1 ng/mL [SD 12.7]) and past (39.5 ng/mL [SD 13.9]) androgen users showed lower serum BDNF levels compared to nonusing controls (51.5 [SD 15.3], p < 0.001, ηp2 = 0.10). BDNF levels were negatively related to maximal strength, and with hormonal status in past androgen users, but no significant associations were found with measures of depression and anxiety.

CONCLUSION:

Lower circulating BDNF concentrations in current and past androgen users suggest that high-dose androgen exposure triggers persistent changes in BDNF expression. Further studies are needed to verify the relationship and its potential clinical implications.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator Neurotrófico Derivado do Encéfalo / Androgênios Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Neuroendocrinology Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Noruega

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator Neurotrófico Derivado do Encéfalo / Androgênios Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Neuroendocrinology Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Noruega